Purpose: Since the combination of cisplatin plus gemcitabine (CG) had a significant survival advantage for the treatment of patients with chemotherapynaïve advanced or metastatic non-small cell lung cancer (NSCLC), CG combination have been evaluated with different schedules. However, the best schedule is still unclear. We designed to compare the efficacy and toxicity of CG combination chemotherapy in two different doses of gemcitabine (1,000 or 1,250 mg/m 2 3-weekly). Materials and Methods: We randomized patients with stage III or IV NSCLC into either gemcitabine 1,250 mg/m 2 or gemcitabine 1,000 mg/m 2 . Patients received cisplatin 60 mg/m 2 intravenously on day1 of each 3-week cycle. Gemcitabine was administered intravenously on days 1 and 8 of each 3-week cycle. Results: From April 2002 until July 2004, 125 patients were enrolled from four university hospitals (55 patients in the gemcitabine 1,000 mg/m 2 arm and 70 patients in the gemcitabine 1,250 mg/m 2 arm). Response rates were not significantly different in both arms (56.4% vs. 55.7%). However, grade 3 neutropenia was significantly lower in gemcitabine 1,000 mg/m 2 arm compared to gemcitabine 1,250 mg/m 2 arm (11.0% vs.
INTRODUCTION
Despite of antismoking efforts and advances in treatment, lung cancer is the most common cause of cancer death worldwide (1, 2) . Among the difficulties in determining the optimal therapy is the fact that advanced non-small cell lung cancer (NSCLC) is a very heterogenous group. However, platinum-based chemotherapy was the most widely used for patients with advanced NSCLC. The combination of cisplatin and gemcitabine (CG) is one of the most active regimens currently available in the treatment of advanced NSCLC.
Platinum-containing regimens, especially CG regimen, achieve response rates ranging from 26% to 54%, with significant survival benefit(3∼10). One of the most commonly used schedules for CG is to deliver cisplatin 100 mg/m 2 on day 1 or 2, and gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 of a 4-week schedule. However, the high incidence of more than grade 3 haematologic toxicities compromises gemcitabine dose intensity (DI), because at least 50% of patients require a reduction in or omission of the day 15 dose (8, 9) . In order to improve compliance while maintaining DI, particularly for gemcitabine, the 4-week schedule was modified in a randomized phase III trial by eliminating day-15 infusion of gemcitabine, increasing the gemcitabine dose to 1,250 mg/m 2 , and shortening the cycle duration to 21 days (11) . The response rate for the 3-week schedule was similar to that achieved with the 4-week schedule. Also a phase II randomized trial demonstrated the superior in the arm with the lower cisplatin dose (100 mg/m 2 vs. 70 mg/m 2 ) with a milder toxicity (12) . In conjunction with these studies, a randomized phase II study showed similar DI in the 3-week schedule to the 4-week schedule of gemcitabine and 70 mg/m 2 of cisplatin (13) .
In this study, we firstly demonstrate 3-week schedule of cisplatin 60 mg/m 2 plus gemcitabine 1,000 mg/m 2 in patients with advanced NSCLC. axial, proton density axial, and contrast-enhanced T1-weighted images as previously described (14) . After we started treatment, all patients were obtained the complete blood count with differential on days 1, 8, and 15 of each cycle.
MATERIALS AND METHODS

1) Eligibility Criteria
3) Treatment Schedules
Patients were randomized into two groups. The protocol dose per infusion for gemcitabine was 1,000 mg/m 2 or 1,250 mg/m 2 .
Gemcitabine was administered intravenously over 30 to 60 min diluted in 125 ml of 5% dextrose water at either dose on days 
4) Dose Adjustments during Treatment
Patients who developed either granulocytopenic fever that required antibiotic therapy or bleeding associated with thrombocytopenia received a 25% dose reduction of both cisplatin and gemcitabine for subsequent treatment cycle. When the neutrophil count was below 0.99×10 9 /L and the platelet count cities, cisplatine and gemcitabine were held.
5) Response and Toxicity Criteria
The response assessment after treatment was performed Common Terminology Criteria for Adverse Events v3.0(15).
6) Statistics
The objective of this study was to conclude that the response rate of 1,000 mg/ 2 regimen is not less than 15% 
RESULTS
1) Patient Characteristics
Between 
2) Tumour Response
All 125 patients were estimated tumor responses (Table 3) after every 2 or 3 cycles. There were 1 CRs (1.8%) and 30
PRs (54.5%) with overall response rate of 56.3% in 1,000 mg/m 2 of gemcitabine group. There were 2 CRs (2.9%) and
37 PRs (52.9%) with overall response rate of 55.8% in 1,250 mg/m 2 of gemcitabine group. There was no statistical differences between two groups (p=0.54).
3) Survival
Median follow-up time was 13.9 months (34 days to 79 months). The median survival was 13.4 months (95% confidence interval [CI], 262 to 540 days) for gemcitabine 1,000 mg group compared with 15.8 months (95% CI, 348 to 600 days) for gemcitabine 1,250 mg group. There were no statistically significant differences in survival between the groups (p=0.979) (Fig. 1) . 
4) Toxicity Evaluation
Myelosuppression was the most common toxicity in both haematologic and non-haematologic toxicities ( All causes of death during the follow-up period were listed on Table 5 .
5) Treatment Delivery and Dose-intensity
The median numbers of cycles of chemotherapy administered were 4 in each treatment groups. A total of 975 times (88.8%) were administered. The planned doses were administered 444 times (92.5%) in patients with 1,000 mg/m 2 of gemcitabine and 531 times (86.0%) in patients with 1,250 mg/m 2 of gemcitabine. Accordingly, the planned doses were administered more frequently in 1,000 mg/m 2 of gemcitabine group than in 1,250 mg/m 2 of gemcitabine group (p=0.046). In the 4 cycles of treatment, 6.5% dose reductions were observed in patients with 1,000 mg/m 2 of gemcitabine group and 12.3% in patients with 1,250 mg/m 2 of gemcitabine group. Sixteen times of total administrations were omitted. In 1,000 mg/m 2 of gemcitabine group, treatments were omitted 5 times bone marrow failure, pneumonia, and patients' denial. In gemcitabine 1,250 mg/m 2 group, 11 times were omitted (bone marrow failure, and denial of treatment, severe grade 4 hepatobiliary toxicities, severe fatigue, and sudden death) ( Table 6 ).
DISCUSSION
In advanced NSCLC, the most commonly used schedule is Several noncomparative phase II studies have indicated that gemcitabine 1,000 mg/m 2 plus cisplatin 70 or 100 mg/m 2 is an effective and relatively well-tolerated treatment for advanced NSCLC (10, 12, 13) . These studies indicated that a gemcitabine The limitation of this study was an unexpectedly higher rate of withdrawal in gemcitabine 1,000 mg/m 2 arm, even though the characteristics of patients between two groups were not significantly different. In the interim analysis, we found that the trend toward similar response rate between the two arms was significant enough to terminate the enrollment earlier.
CONCLUSION
Tri-weekly gemcitabine 1,000 mg/m 2 plus cisplatin regimen demonstrated similar response rates with lesser haematologic toxicity profiles especially granulocytopenia and anaemia compared with 3-weekly gemcitabine 1,250 mg/m 2 plus cisplatin regimen. Despite the small sample size, we might conclude that 3-weekly gemcitabine 1,000 mg/m 2 plus cisplatin regimen provides a feasible alternative chemotheutic option for patients with advanced NSCLC.
